TABLE 3.
Mechanism of drugs treating diabetic complications.
| Drugs | Diseases | Mechanism | Reference |
|---|---|---|---|
| Melatonin | Diabetic Cardiomyopathy | inhibits lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/Smads signaling | (Che et al., 2020c) |
| Melatonin | Diabetic Retinopathy | inhibits NLRP3 inflammasome by upregulating MEG3/miR-204/Sirt1 axis | Tu et al. (2020) |
| Metformin | Diabetic Periodontitis | inhibits lncRNA NEK7 to improve NLRP3 inflammasome-mediated pyroptosis | Zhou et al. (2020) |
| Atorvastatin | Diabetic Neuropathy | inhibits NLRP3 expression by regulating MALAT1/miR-200c/NRF2 axis | Zuo et al. (2021) |
| Sinapic acid | Diabetic Atherosclerosis | inhibits lncRNA-MALAT1 to downregulate NLRP3 expression | Han et al. (2018) |
MALAT1, metastasis-associated lung adenocarcinoma transcript 1; miR, miRNA; TGF-β1, transforming growth factor β1; MEG3, maternally expressed 3; NEK7, NIMA-related kinases 7; NRF2, nuclear factor erythroid-2-related factor 2.